Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline

Drugs of Today

Volumn 41, Issue 6, 2005, Pages 369-391

  Youdim, Moussa B H ^a   Maruyama, Wakako ^b   Naoi, Makato ^c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^c GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE; AMYLOID PRECURSOR PROTEIN; CLORGYLINE; DOPAMINE; FLUOXETINE; LADOSTIGIL; LAZABEMIDE; LEVODOPA; META TYRAMINE; METHAMPHETAMINE; MILACEMIDE; MONOAMINE OXIDASE B INHIBITOR; NEUROTOXIN; NOMIFENSINE; RASAGILINE; RESERPINE; SELEGILINE; SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA; TRYPTOPHAN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL MODEL; ANOXIA; BRAIN ISCHEMIA; DEGENERATIVE DISEASE; DOPAMINE RELEASE; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HEAD INJURY; HUMAN; HUMAN CELL; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LONG TERM POTENTIATION; NERVE CELL CULTURE; NERVE CELL PLASTICITY; NERVOUS SYSTEM INJURY; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN PROCESSING; RAT; REVIEW;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; HUMANS; INDANS; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS;

EID: 23144441835     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.6.893613     Document Type: Review

References (159)

1. Collins, G.G., Sandler, M., Williams, E.D., Youdim, M.B. Multiple forms of human brain mitochondrial monoamine oxidase. Nature 1970, 225:817-20.
2. Squires, R.F. Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv Biochem Psychopharmacol 1972, 5: 355-7.
3. O'Carroll, A.M., Fowler, C.J., Phillip, J.P., Tobia, I., Tipton, K.F. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 1983, 322: 198-207.
4. Knoll and Magyar. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972, 5: 393-408.
5. Birkmayer, W., Riederer, P., Youdim, M.B., Linauer, W. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm 1975, 36: 303-26.
6. Birkmayer, W., Riederer, P., Ambrozi, L., Youdim, M.B. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet 1977, 1: 439-43.
7. Lees, A.J., Shaw, K.M., Kohout, L.J. et al. Deprenyl in Parkinson's disease. Lancet 1977, 2: 791-5.
8. Parkinson Study Group (Datatop). Selegiline and Parkinson's disease. N Engl J Med 1989, 321: 1364-71.
9. Birkmayer, W., Knoll, J., Riederer, P., Youdim, M.B., Hars, V., Marton, J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A long-term study. J Neural Transm 1985, 64: 113-27.
10. Riederer, P., Rinne U.K. Selegiline in Parkinson's Disease: An update. Mov Disords 1992, 8 (Suppl. 1): 51-44.
11. Maycock, A.L., Abeles, R.H., Salach, J., Singer, T.P. The action of acetylenic inhibitors on mitochondrial monoamine oxidase: Structure of the flavin site in the inhibited enzyme. Ciba Foundation Symposium, Elsevier, Amsterdam 1976, 39: 33-49.
12. 14C-deprenyl. J Neural Transm 1978, 43: 199-208.
13. Reynolds, G.P., Riederer, P., Sandler, N.R., Jellinger, K., Seemali, D. Amphetamine and 2-phenylethylamine in post mortem Parkinson brains after I-deprenyl administration. J Neural Transm 1978, 3: 271-8.
14. Green, A.R., Youdim, M.B. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol 1975, 55: 415-22.
15. Simpson, L.L. Evidence that deprenyl, a type B monoamine oxidase inhibitor is an indirectly acting sympathomimetic amine. Biochem Pharmacol 1978, 27: 1591-5.
16. Finberg, J.P.M., Tenne, M., Youdim, M.B.H. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 1981, 73: 65-74.
17. Youdim, M.B.H., Finberg, J.P.M., Levy, R. et al. R-Enantiomers of N-propargyl-aminoindan compounds. Their preparation and pharmaceutical composition containing them. US Patent 1995, 5: 457, 133; NCI 1420, 1-8.
18. Sterling, J., Veinberg, A., Lerner, D. et al. (R) (+)-N-propargyl-1- aminoindan (rasagiline) and derivatives: Highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm Suppl 1998, 52: 301-5.
19. Sterling, J., Herzig, Y., Goren, T. et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J Med Chem 2002, 45: 5260-79.
20. Sabbagh, A., Youdim, M.B.H. Selective inhibition of monoamine oxidase type B by propargyl-containing drugs. Israel J Med Sci 1978, 14: 1097.
21. Kalir, A., Sabbagh, A., Youdim, M.B.H. Selective "suicide" acetylenic and reversible inhibitors of monoamine oxidase A and B. Br J Pharmacol 1981, 73: 55-64.
22. Youdim, M.B.H., Gross, A., Finberg, J.P.M. Rasagiline [N-Propargyl-1R(+)-aminoindant], A selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001, 132: 500-6.
23. Youdim, M.B., Finberg, J.P. MAO type B inhibitors as adjunct to L-dopa therapy. Adv Neurol 1987, 45: 127-36.
24. Finberg, J.P., Wang, J., Bankiewicz, K., Harvey-White, J., Kopin, I.J., Goldstein, D.S. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm 1998, 52: 279-85.
25. Finberg, J.P., Lamensdorf, I., Weinstock, M., Schwartz, M., Youdim, M.B. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol 1999, 80: 495-9.
26. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch Neurol 2002, 59: 1937-43.
27. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004, 61: 561-6.
28. Finberg, J.P.M., Youdim, M.B.H. Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors of types A and B in the cat. Br J Pharmacol 1985, 85: 541-6.
29. Rabey, J.M., Sagi, I., Huberman, M. et al.; Rasagiline Study Group. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000, 23: 324-30.
30. Largo Study Group, 2003 (unpublished data).
31. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parksinson disease and motor fluctuations. The PRESTO Study. Arch Neurol 2005, 62: 241-8.
32. 14C]-deprenyl. Mol Pharmacol 1978, 16: 234-41.
33. Youdim, M.B.H., Finberg, J.P.M., Tipton, K.F. Monoamine Oxidases. In: Weiner, N., Trendelenburg, U. (Eds.). Handbook of Experimental Pharmacology Catecholamine II. Springer-Verlag, Berlin 1998, pp. 415-58.
34. Kearney, FB., Salach, J.I., Walker, W.H. et al. The covalently bound flavin of hepatic monoamine oxidase I. Isolation and sequence of a flavin peptide and evidence for binding to the 8-position. Eur J Biochem 1971, 24: 321-7.
35. Bach, A.W.J., Lan, N.C., Johnson, D.L. et al. cDNA cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties. Proc Nat Acad Sci USA 1988, 85: 4934-8.
36. Salach, J., Singer, T.P., Yaunobu, K.T., Monamura, N., Youdim, M.B.H. Cysteinyl flavin in monoamine oxidase from the central nervous system. Ciba Foundation Symposium, Elsevier, Amsterdam 1976, 39: 49-57.
37. Holzbauer, M., Youdim, M.B. The oestrous cycle and monoamine oxidase activity. Br J Pharmacol 1973, 48: 600-8.
38. Fowler, J.S., Volkow, N.D., Logan, J. et al. Slow recovery of human brain MAO B after deprenyl (selegiline) withdrawal. Synapse 1994, 18: 86-93.
39. Youdim, M.B., Banerjee, D.K., Keiner, K., Offutt, L., Pollard, H.B. Steroid regulation of monoamine oxidase activity in the adrenal medulla. FASEB J 1989, 3: 1753-9.
40. Youdim, M.B., Riederer, P. The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease. Mov Disord 1993, 8 (Suppl. 1): S8-S13.
41. Youdim, M.B., Tipton, K.F. Rat striatal monoamine oxidase-B inhibition by i-deprenyl and rasagiline: Its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. Parkinsonism Relat Disord 2002, 8: 247-53.
42. Youdim, M.B.H., Wadia, A., Tatton, N.A., Weinstock, M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 2001, 939: 450-8.
43. Gotz, M.E., Breithaupt, W., Sautter, J. et al. Chronic TVP-1012 (rasagiline) dose-activity response of monoamine oxidases A and B in the brain of the common marmoset. J Neural Transm 1998, 52(Suppl.): 271-8.
44. Riederer, P., Youdim, M.B. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with I-deprenyl. J Neurochem 1986, 46: 1359-65.
45. Green, A.R., Tordoff, A., Mitchel, B., Youdim, M.B.H. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for degree of inhibition of enzyme necessary for increased function and activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol 1977, 60: 343-9.
46. Riederer, P., Konradi, C., Schay, V. et al. Localization of MAO-A and MAO-B in human brain: A step in understanding the therapeutic action of L-deprenyl. Adv Neurol 1986, 45: 111-8.
47. Neff, N.H., Gordis, C. Neuronal monoamine oxidase: Specific enzyme types and their rates of formation. Adv Biochem Psychopharmacol 1972, 5: 307-24.
48. Della Corte, L., Tipton, K.F. The turnover of the A and B-forms of monoamine oxidase in rat liver. Biochem Pharmacol 1980, 29: 811-5.
49. Finberg, J.P., Youdim, M.B. Pharmacological properties of the anti-Parkinson drug rasagiline, modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 2002, 43: 1110-18.
50. Finberg, J.P., Tenne, M. Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br J Pharmacol 1982, 77: 13-21.
51. Youdim, M.B.H. Rasagiline - An anti-Parkinson drug with neuroprotective activity. Fut Drug Expert Neurotherap Rev 2003, 3: 737-49.
52. Lamensdorf, I., Youdim, M.B., Finberg, J.P. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 1996, 67: 1532-9.
53. Finberg, J.P., Takeshima, T., Johnston, J.M., Commissiong, J.W. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 1998, 9: 703-7.
54. Lamensdorf, L., Youdim, M.B., Finberg, J.P. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 1996, 67: 1532-9.
55. Lamensdorf, I., Porat, S., Simantov, R., Finberg, J.P. Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. Br J Pharmacol 1999, 126: 997-1002.
56. Yang, H.Y., Neff, N.H. Beta-phenylethylamine: A specific substrate for type B monoamine oxidase of brain. J Pharmacol Exp Ther 1973, 187: 365-71.
57. Maitre, L., Delini-Stula, A., Waldmeier, P.C. Relation between the degree of monoamine oxidase inhibition and some psychopharmacological responses to monoamine oxidase inhibitors. Ciba Foundation Symposium, Elsevier, Amsterdam 1976, 39: 247-67.
58. Riederer, P., Youdim, M.B., Rausch, W.D., Birkmayer, W., Jellinger, K., Seemann, D. On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm 1978, 43: 217-26.
59. Neff, N.H., Yang, H.Y., Fuentes, J.A. The use of selective monoamine oxidase inhibitor drugs to modify amine metabolism in brain. Adv Biochem Psychopharmacol 1974, 12: 49-57.
60. Janssens de Varebeke, P., Pauwels, G., Buyse, C. et al. The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B. J Neurochem 1989, 53: 1109-16.
61. Youdim, M.B., Riederer, P. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm Gen Sect 1993, 91: 181-95.
62. Heikkila, R.E., Duvoisin, R.C., Finberg, J.P., Youdim, M.B.H. Prevention of MPTP neurotoxicity by AGN1133 and AGN-1135, selective inhibitors of monoamine oxidase. B Eur J Pharmacol 1985, 116:3 13-7.
63. Speiser, Z., Katzir, O., Rehavi, M., Zabarski, T., Cohen, S. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol Biochem Behav 1998, 60: 387-93.
64. Speiser, Z., Levy, R., Cohen, S. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl 1998, 52: 287-300.
65. Huang, W., Chen, Y., Shohami, E., Weinstock, M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 1999, 366: 127-35.
66. Waibel, S., Reuter, A., Malessa, S., Blaugrund, E., Ludolph, A.C. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol 2004, 251: 1080-4.
67. Blandini, F., Armentero, M.T., Fancellu, R., Blaugrund, E., Nappi, G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol 2004, 187: 455-9.
68. Ravina, B.M., Fagan, S.C., Hart, R.G. et al. Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment. Neurology 2003, 22, 60: 1234-40.
69. Maruyama, W., Naoi, M. Neuroprotection by (-)-deprenyl and related compounds. Mech Ageing Dev 1999, 111: 189-200.
70. Maruyama, W., Youdim, M.B.H., Naoi, M. Anti-apoptotic function of N-propargylamine-1(R)-and (S)-aminoindan, Rasagiline and TV1022. Ann NY Acad Sci 2000, 939: 320-9.
71. Maruyama, W., Akao, Y., Youdim, M.B.H., Naoi, M. Neurotoxins induce apoptosis in dopamine neurons: Protection by N-propargylamine 1(R)-and (S)-aminoindan, rasagiline and TV1022. J Neural Transm 2000, 60: 171-86.
72. Maruyama, W., Boulton, A. A., Davis, B.A., Dostert, P., Naoi, M. Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: Suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine. J Neural Transm 2001, 108: 11-24.
73. Maruyama, W., Akao, Y., Youdim, M.B., Davis, B.A., Naoi, M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergicneurotoxin, N-methyl(R)salsolinol. J Neurochem 2001, 78: 727-35.
74. Maruyama, W., Akao, Y., Carrillo, M.C., Kitani, K., Youdium, M.B., Naoi, M. Neuroprotection by propargylamines in Parkinson's disease: Suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 2002, 24: 675-82.
75. Maruyama, W., Takahashi, T., Youdim, M., Naoi, M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 2002, 109:467-81.
76. Youdim, M.B.H., Weinstock, M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug, TV3326, [(N-propargyl-(3R)aminoindan-5-yl)-ethyl methyl carbamate]. Cell Mol Neurobiol 2002, 21: 555-73.
77. Tatton, N.A. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 2000, 166: 29-43.
78. Tatton, W.G., Chalmers-Redman, R.M., Ju, W.J. et al. Propargylamines induce anti-apoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Therap 2002, 301, 753-64.
79. Maruyama, W., Weinstock, M., Youdim, M.B., Nagai, M., Naoi, M. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)- aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 2003, 341: 233-6.
80. Maruyama, W., Akao, Y., Carrillo, M.C., Kitani, K., Youdium, M.B., Naoi, M. Neuroprotection by propargylamines in Parkinson's disease: Suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 2002, 24: 675-82.
81. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993, 328: 176-83.
82. Abu-Raya, S., Blaugrund, E., Trembovler, V., Shilderman-Bloch, E., Shohami, E., Lazarovici, P. Rosagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. J Neurosci Res 1999, 58: 456-63.
83. Abu-Raya, S., Tabakman, R., Blaugrund, E., Trembovler, V., Lazarovici, P. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 2002, 434: 109-16P.
84. Bar Am, O., Amit, T., Youdim, M.B.H. Contrasting neuroprotective and neurotoxic actions of respective metabolites of antiparkinson drugs rasagiline and selegiline. Neurosci Lett 2004, in press.
85. Speiser, Z., Mayk, A., Eliash, S., Cohen, S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm 1999, 106: 59.
86. Oh, C., Murray, B., Bhattacharya, N., Holland, D., Tatton, W.G. (-)-Deprenyl alters the survival of adult murine facial motoneurons after axotomy: Increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants. J Neurosci Res 1994, 38: 64-74.
87. Youdim, M.B., Weinstock, M. Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mech Ageing Dev 2002, 123: 1081-6.
88. Carrillo, M.C., Minami, C., Kitani, K. et al. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 2000, 67: 577-85.
89. Youdim, M.B., Heldman, E., Pollard, H.B., Fleming, P., McHugh, E. Contrasting monoamine oxidase activity and tyramine induced catecholamine release in PC12 and chromaffin cells. Neuroscience 1986, 19: 1311-8.
90. Naoi, M., Maruyama, W., Akao, Y., Yi, H. Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines. J Neural Transm 2002, 109: 607-21.
91. Gassen, M., Lamensdorf, I., Armony, T., Finberg, J.P., Youdim, M.B. Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: Microdialysis study on dopamine release and free radical generation. J Neural Transm 2003, 110: 171-82.
92. Pellegrini-Giampietro, D.E., Peruginelli, F., Meli, E. et al. Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: Time-course and mechanisms. Neuropharmacology 1999, 38: 1607-19.
93. Sagi, Y., Mandel, S., Youdim, M.B.H. Genomic and proteomic profiling of the neuroprotective mechanism of rasagiline in the mouse model of PD. Neural Plsticity 2003, 10: 227.
94. Belzacq, A.S., Brenner, C. The adenine nucleotide translocator: A new potential chemotherapeutic target. Curr Drug Targets 2003, 7: 517-24, review.
95. Belzacq, A.S., Vieira, H.L., Kroemer, G., Brenner, C. The adenine nucleotide translocator in apoptosis. Biochimie 2002, 84: 167-76.
96. Belzacq, A.S., Vieira, H.L., Kroemer, G., Brenner, C. The adenine nucleotide translocator in apoptosis. Biochimie 2002, 84: 167-76.
97. Halestrap, A.P., McStay, G.P., Clarke, S.J. The permeability transition pore complex: Another view. Biochimie 2002, 84: 153-66.
98. Suleiman, M.S., Halestrap, A.P., Griffiths, E.J. Mitochondria: A target for myocardial protection. Pharmacol Ther 2001, 89: 29-46.
99. Akao, Y., Maruyama, W., Shimizu, S. et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bc1-2 and rasagiline, N-propargyl-1 (R)-aminoindan. J Neurochem 2002, 82: 913-23.
100. Weinreb, O., Mandel, S., Youdim, M.B. cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J 2003, 17: 935-7.
101. Yogev-Falach, M., Amit, T., Bar-Am, O., Youdim M.B. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J 2003, 17: 2325-7.
102. Bar Am, O., Amit, T., Weinreb, O., Yogev-Falach, M., Youdim, M.B.H. The neuroprotective activity of rasagiline and its propargyl moiety is dependent on activation/gene expression of protein kinase C (PKC). Neural Plasticity 2003, 10: 183.
103. Weinreb, O., Bar Am, O., Chilag-Tamar, O., Amit, T., Youdim, M.B.H. Gene and protein expression profiles of neuroprotective and anti-apoptotic action of rasagiline in PC-12 cell cultures. Neural Plasticity 2003, 10: 238.
104. Constantini, L.C., Cole, D., Chatuvedi, P., Isacson, P. Immunophilin ligands can prevent progressive e dopaminergic degeneration in animal models of Parkinson's disease. J Eur Neurosci 2001, 13: 1085-92.
105. Akao, Y., Maruyama, W., Yi, H., Shamoto-Nagai, M., Youdim, M.B., Naoi, M. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 2002, 326: 105-8.
106. Sagi, Y., Weinstock, M., Youdim, M.B.H. Attenuation of MPTP-Induced Dopaminergic Neurotoxicity by TV3326, A cholinesterase-monoamine oxidase inhibitor. J Neurochem 2003, 2: 290-7.
107. Nishizuka, Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1998, 334: 661-5.
108. Montz, H.P., Davis, G.E., Skaper, S.D., Manthorpe, M., Varon, S. Tumor-promoting phorbol diester mimics two distinct neuronotrophic factors. Brain Res 1985, 355: 150-4.
109. Hama, T., Huang, K.P., Guroff, G. Protein kinase Casa component of a nerve growth factor-sensitive phosphorylation system in PC12 cells. Proc Natl Acad Sci USA 1986, 83: 2353-7.
110. Vianna, M.R., Barros, D.M., Silva, T. et al. Pharmacological demonstration of the differential involvement of protein kinase C isoforms in short- and long-term memory formation and retrieval of one-trial avoidance in rats. Psychopharmacology (Berl) 2000, 150: 77-84.
111. Jin, L.W., Saitoh, T. Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy. Drugs Aging 1995, 6: 136-49.
112. Masliah, E., Cole, G.M., Hansen, L.A. et al. Protein kinase C alteration is an early biochemical marker in Alzheimer's disease. J Neurosci 1991, 11: 2759-67.
113. Shimohama, S., Narita, M., Matsushima, H., Kimura, J., Kameyama, M., Hagiwara M., Hidaka, H., Taniguchi, T. Assessment of protein kinase C isozymes by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease. Neurology 1993, 43: 1407-13.
114. 2+-independent protein kinase C changes in the brain of patients with Alzheimer's disease. J Neurochem 1996, 67: 317-23.
115. Roth, G.S., Joseph, J.A., Mason, R.P. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci 1995, 18: 203-6.
116. Wang, H.Y., Pisano, M.R., Friedman, E. Attenuated protein kinase C activity and translocation in Alzheimer's disease brain. Neurobiol Aging 1994, 15: 293-8.
117. Buxbaum, J.D., Gandy, S.E., Cicchetti, P. et al. Processing of Alzheimer beta/A4 amyloid precursor protein: Modulation by agents that regulate protein phosphorylation. Proc Natl Acad Sci USA 1990, 87: 6003-6.
118. Nitsch, R.M., Slack, B.E., Wurtman, R.J., Growdon, J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992, 258: 304-7.
119. Slack, B.E., Nitsch, R.M., Livneh, E. et al. Regulation by phorbol esters of amyloid precursor protein release from Swiss 3T3 fibroblasts overexpressing protein kinase C alpha. J Biol Chem 1993, 268: 21097-101.
120. Checler, F. Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. J Neurochem 1995, 65: 1431-44.
121. Caputi, A., Barindelli, S., Pastorino, L. et al. Increased secretion of the amino-terminal fragment of amyloid precursor protein in brains of rats with a constitutive up-regulation of protein kinase C. J Neurochem 1997, 68: 2523-9.
122. Rossner, S., Ueberham, U., Yu, J. et al. In vivo regulation of amyloid precursor protein secretion in rat neocortex by cholinergic activity. Eur J Neurosci 1997, 9: 2125-34.
123. Lin, L., Georgievska, B., Mattsson, A., Isacson, O. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc Natl Acad Sci USA 1999, 96: 12108-13.
124. Yogev-Falach, M., Amit, T., Bar-Am, O., Weinstock, M., Youdim, M.B.H. The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 2002, 16: 1674-6.
125. Bar Am, O., Yogev-Falach, M., Amit, T., Sagi, Y., Youdim, M.B. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 2004b, 89: 1119-25.
126. Ruvolo, P.P., Deng, X., Carr, B.K., May, W.S. A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 1998, 273: 25436-42.
127. Quo, B.C., Xu, Y.H. Bcl-2 over-expression and activation of protein kinase C suppress the trail-induced apoptosis in Jurkat T cells. Cell Res 2001, 11: 101-6.
128. Weinreb, O., Bar-Am, O., Amit, T., Chillag-Talmor, O., Youdim, M.B. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 2004, 18: 1471-3.
129. Kribben, A., Wieder, E.D., Li, X. et al. AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. Am J Physiol 1993, 265: C939-45.
130. Maher, P. How protein kinase C activation protects nerve cells from oxidative stress-induced cell death. J Neurosci 2001, 21: 2929-38.
131. Tsujimoto, Y., Shimizu, S. Bcl-2 family: life-or-death switch. FEBS Lett 2000, 466: 6-10.
132. Aderem, A. The MARCKS brothers: A family of protein kinase C substrates. Cell 1992, 71: 713-6.
133. Heemskerk, F.M., Chen, H.C., Huang F.L. Protein kinase C phosphorylates Ser152, Ser156 and Ser163 but not Ser160 of MARCKS in rat brain. Biochem Biophys Res Commun 1993, 190: 236-41.
134. Blackshear, P.J. The MARCKS family of cellular protein kinase C substrates. J Biol Chem 1993, 268: 1501-4.
135. McNamara, R.K., Lenox, R.H. Distribution of the protein kinase C substrates MARCKS and MRP in the postnatal developing rat brain. J Neurol 1998, 397: 337-56.
136. McNamara, R.K., Stumpo, D.J., Morel, L.M. et al. Effect of reduced myristoylated alanine-rich C kinase substrate expression on hippocampal mossy fiber development and spatial learning in mutant mice: Transgenic rescue and interactions with gene background. Proc Natl Acad Sci USA 1998, 95: 14517-22.
137. Saitoh, T., Horsburgh, K., Masliah, E. Hyperactivation of signal transduction systems in Alzheimer's disease. Ann NY Acad Sci 1993, 695: 34-41.
138. Mochly-Rosen, D. Localization of protein kinases by anchoring proteins: A theme in signal transduction. Science 1995, 268: 247-51.
139. Battaini, F., Pascale, A., Paoletti, R., Govoni, S. The role of anchoring protein RACK1 in PKC activation in the ageing rat brain. Trends Neurosci 1997, 20: 410-5.
140. Battaini, F., Pascale, A., Lucchi, L., Pasinetti, G.M., Govoni, S. Protein kinase C anchoring deficit in postmortem brains of Alzheimer's disease patients. Exp Neurol 1999, 159: 559-64.
141. Gasparini, L., Racchi, M., Binetti, G. et al. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease. FASEB J 1998, 12: 17-34.
142. Mills, J., Reiner, P.B. Regulation of amyloid precursor protein cleavage. J Neurochem 1999, 72: 443-60.
143. Benussi, L., Govoni, S., Gasparini, L. et al. Specific role for protein kinase C alpha in the constitutive and regulated secretion of amyloid precursor protein in human skin fibroblasts. Neurosci Lett 1998, 240: 97-101.
144. Kinouchi T., Sorimachi H., Maruyama K. et al. Conventional protein kinase C (PKC)-alpha and novel PKC epsilon, but not -delta, increase the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein from PKC cDNA transfected 3Y1 fibroblasts. FEBS Lett 1995, 364: 203-6.
145. Yeon, S.W., Jung, M.W., Ha, M.J. et al. Blockade of PKC epsilon activation attenuates phorbol ester-induced increase of alpha-secretase-derived secreted form of amyloid precursor protein. Biochem Biophys Res Commun 2001, 280: 782-7.
146. Maruyama, W., Nitta, A., Shamoto-Nagai, M. et al. N-Propargyl-l (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int 2004, 44: 393-400.
147. Grilli, M., Memo, M. Nuclear factor-KB/Rel proteins: A point of convergence of signaling pathway relevant in neuronal function and dysfunction. Biochem Pharmacol 1999, 57: 1-7.
148. Kaltschmidt, B., Uherek, M., Volk, B., Baeuerle, P.A., Kaltschmidt, C. Transcription factor NF-κB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA 1997, 94: 2642-7.
149. Hunot, S., Brugg, B., Ricard, D. et al. Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci USA 1997, 94: 7531-6.
150. Qin, Z.H., Wang, Y., Nakai, M., Chase, T.N. Nuclear factor-κB contributes to excitotoxin-induced apoptosis in rat striatum. Mol Pharmacol 1998, 53: 33-42.
151. Shou, Y., Li, N., Li, L., Borowitz, J.L., Isom, G.F. NFκ-B-mediated up-regulation of Bcl-Xs and Bax contributes to cytochrome c release in cyanide-induced apoptosis. J Neurochem 2002, 81: 842-8.
152. Goodman, Y., Mattson, M.P. Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid beta-peptide toxicity. J Neurochem 1996, 66: 869-72.
153. Karin, M., Ben-Neriah, Y. Phosphorylation meets ubiquitination: The control of NF-κB activity. Ann Rev Immunol 2000, 18: 621-63.
154. Weber, C.K., Liptay, S., Wirth, T., Adler, G., Schinid, R.M. Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases alpha and beta. Gastroenterology 2000, 119: 1209-18.
155. Kaltschmidt, B., Uherek, M., Wellmann, H., Volk, B., Kaltschmidt, C. Inhibition of NF-κB potentiates amyloid β-mediated neuronal apoptosis. Proc Natl Acad Sci USA 1999, 96: 9409-19.
156. Wang, L., Muramatsu, S., Lu, Y. et al. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther 2002, 9: 381-9.
157. Palfi, S., Leventhal, L., Chu, Y. et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigro-striatal degeneration. J Neurosci 2002, 22: 4942-54.
158. Nutt, J.G., Burchiel, K.J., Cornelia, C.L. et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 14: 69-73.
159. Gill, S.S., Patel, N.K., Hotton, G.R. et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nature Med 2003, 9: 589-95.